Revolution Medicines Inc

RVMD

Add to Watchlist

147.810USD

+2.090+1.43%

Market hours （ET）Quotes delayed by 15 min

Revolution Medicines Inc's Score

Industry at a Glance

Industry Ranking

32 / 383

Overall Ranking

128 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Revolution Medicines Inc Highlights

StrengthsRisks

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -20.50, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 218.01M shares, increasing 4.82% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 950.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.13.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

180.316

Target Price

+27.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Revolution Medicines Inc is 5.20, ranking 367 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.20

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.73

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Revolution Medicines Inc is 6.63, ranking 234 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.50, which is -72.57% below the recent high of -5.62 and -23.82% above the recent low of -25.39.

Score

Industry at a Glance

Previous score

6.63

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 32/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Revolution Medicines Inc is 8.86, ranking 46 out of 383 in the Biotechnology & Medical Research industry. The average price target is 76.50, with a high of 99.00 and a low of 70.00.

Score

Industry at a Glance

Previous score

8.86

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Revolution Medicines Inc is 9.07, ranking 53 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 157.27 and the support level at 132.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.94

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Revolution Medicines Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 102.55%, representing a quarter-over-quarter decrease of 1.87%. The largest institutional shareholder is PRFDX, holding a total of 3.23M shares, representing 1.52% of shares outstanding, with 47.86% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Farallon Capital Management, L.L.C.

14.58M

-0.29%

Janus Henderson Investors

12.30M

+8.34%

Baker Bros. Advisors LP

9.46M

--

Fidelity Management & Research Company LLC

8.59M

-8.65%

BlackRock Institutional Trust Company, N.A.

7.92M

+5.69%

Nextech Invest, Ltd.

7.60M

--

Wellington Management Company, LLP

6.99M

-28.80%

Paradigm BioCapital Advisors LP

6.64M

+6.77%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Revolution Medicines Inc is 6.55, ranking 22 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Revolution Medicines Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Revolution Medicines Inc

RVMD

7.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment